10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2020 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 25, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Operating Activities: | |||
| Net income | $ 89 | 5,364 | 5,460 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 288 | 255 | 226 |
| Amortization expense | 1,192 | 1,149 | 1,203 |
| Stock-based compensation expense | 643 | 636 | 845 |
| Deferred income taxes | (214) | (2,098) | 289 |
| Net (gains) losses from equity securities | 1,662 | (1,241) | (115) |
| Acquired in-process research and development expenses | 5,856 | 4,251 | 0 |
| In-process research and development impairment | 0 | 800 | 820 |
| Write-downs for slow moving and excess raw material and work in process inventory | 40 | 547 | 440 |
| Other | 250 | 279 | 171 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (1,171) | (218) | 480 |
| Inventories | (195) | (95) | (310) |
| Prepaid expenses and other | (214) | (307) | 903 |
| Accounts payable | 80 | (61) | (39) |
| Income taxes payable | (778) | 272 | (1,459) |
| Accrued liabilities | 640 | (389) | (514) |
| Net cash provided by operating activities | 8,168 | 9,144 | 8,400 |
| Investing Activities: | |||
| Purchases of marketable debt securities | (20,315) | (30,455) | (10,233) |
| Proceeds from sales of marketable debt securities | 23,239 | 7,523 | 1,522 |
| Proceeds from maturities of marketable debt securities | 9,479 | 22,398 | 24,336 |
| Acquisitions, including in-process research and development, net of cash acquired | (25,742) | (4,251) | 0 |
| Purchases of equity securities | (455) | (1,773) | (156) |
| Capital expenditures | (650) | (825) | (924) |
| Other | (171) | (434) | (190) |
| Net cash (used in) provided by investing activities | (14,615) | (7,817) | 14,355 |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 8,184 | 0 | 0 |
| Proceeds from issuances of common stock | 256 | 209 | 289 |
| Repurchases of common stock | (1,583) | (1,749) | (2,900) |
| Repayments of debt and other obligations | (2,500) | (2,750) | (6,250) |
| Payment of dividends | (3,449) | (3,222) | (2,971) |
| Other | (138) | (122) | (486) |
| Net cash provided by (used in) financing activities | 770 | (7,634) | (12,318) |
| Effect of exchange rate changes on cash and cash equivalents | 43 | (2) | (85) |
| Net change in cash and cash equivalents | (5,634) | (6,309) | 10,352 |
| Cash and cash equivalents at beginning of period | 11,631 | 17,940 | |
| Cash and cash equivalents at end of period | 5,997 | 11,631 | 17,940 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 951 | 982 | 1,070 |
| Income taxes paid | 2,639 | 1,793 | 3,198 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |